{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:29:32Z","timestamp":1790713772244,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"The Roman-Epstein Research Foundation"},{"name":"Prusiner-Abramsky Award"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bcmd.2016.10.028","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T21:16:40Z","timestamp":1478899000000},"page":"117-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development"],"prefix":"10.1016","volume":"68","author":[{"given":"Yuval","family":"Ishay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Szer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tama","family":"Dinur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Ilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Arkadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2016.10.028_bb0005","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/01.wnl.0000252807.38124.a3","article-title":"How common are the \u201ccommon\u201d neurologic disorders?","volume":"68","author":"Hirtz","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.bcmd.2016.10.028_bb0010","first-page":"691","article-title":"Occurrence of Parkinson's syndrome in type I Gaucher disease","volume":"89","author":"Neudorfer","year":"1996","journal-title":"QJM Mon. J. Assoc. Phys."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0015","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa033277","article-title":"Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews","volume":"351","author":"Aharon-Peretz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0020","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0025","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs mild GBA mutations on Parkinson disease","volume":"84","author":"Gan-Or","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.bcmd.2016.10.028_bb0030","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/jamaneurol.2014.313","article-title":"Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes","volume":"71","author":"Alcalay","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/(SICI)1096-8652(199907)61:3<216::AID-AJH12>3.0.CO;2-B","article-title":"Parkinson's syndrome preceding clinical manifestation of Gaucher's disease","volume":"61","author":"Machaczka","year":"1999","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0040","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bcmd.2012.11.011","article-title":"Phenotype in patients with Gaucher disease and Parkinson disease","volume":"50","author":"Chetrit","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0045","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/humu.22124","article-title":"Gaucher disease paradigm: from ERAD to comorbidity","volume":"33","author":"Bendikov-Bar","year":"2012","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0050","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","article-title":"ER stress and autophagic perturbations lead to elevated extracellular \u03b1-synuclein in GBA-N370S Parkinson's iPSC-derived dopamine neurons","volume":"6","author":"Fernandes","year":"2016","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","article-title":"The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry","volume":"46","author":"Rosenbloom","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0060","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s00415-013-7011-2","article-title":"Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease","volume":"260","author":"B\u00f6ttcher","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0065","first-page":"388","article-title":"Gaucher's disease: a disease with chronic stimulation of the immune system","volume":"106","author":"Shoenfeld","year":"1982","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0070","first-page":"205","article-title":"Cytokines in Gaucher's disease","volume":"10","author":"Barak","year":"1999","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1615\/CritRevOncog.2013004503","article-title":"Immunological cells and functions in Gaucher disease","volume":"18","author":"Pandey","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ajh.2830290403","article-title":"Polyclonal B-cell lymphocytosis and hypergammaglobulinemia in patients with Gaucher disease","volume":"29","author":"Marti","year":"1988","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0085","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/icb.2009.42","article-title":"Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent","volume":"87","author":"Ilan","year":"2009","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0090","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrm2329","article-title":"Principles of bioactive lipid signalling: lessons from sphingolipids","volume":"9","author":"Hannun","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0095","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMra1104901","article-title":"The human plasma lipidome","volume":"365","author":"Quehenberger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0100","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bcmd.2007.09.002","article-title":"Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy","volume":"40","author":"Langeveld","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0105","first-page":"151","article-title":"\u03b2-Glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model","volume":"7","author":"Zigmond","year":"2014","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2015.47","article-title":"Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel disease","volume":"5","author":"Ilan","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0115","series-title":"Williams Hematol","first-page":"1121","article-title":"Gaucher disease and related lysosomal storage diseases","author":"Zimran","year":"2015"},{"key":"10.1016\/j.bcmd.2016.10.028_bb0120","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF01541326","article-title":"Natural autoantibodies in sera of patients with Gaucher's disease","volume":"15","author":"Shoenfeld","year":"1995","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0125","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.atherosclerosis.2008.08.027","article-title":"Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease","volume":"204","author":"de Fost","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bcmd.2016.10.028_bb0130","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2004-12-4672","article-title":"Gaucher disease and cancer incidence: a study from the Gaucher Registry","volume":"105","author":"Rosenbloom","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.10.028_bb0135","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bcmd.2005.03.004","article-title":"Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic","volume":"34","author":"Zimran","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0140","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/01.tp.0000252783.66886.f3","article-title":"Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T lymphocyte plasticity","volume":"83","author":"Ilan","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.bcmd.2016.10.028_bb0145","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gut.2006.095497","article-title":"Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders","volume":"56","author":"Zigmond","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.bcmd.2016.10.028_bb0150","doi-asserted-by":"crossref","first-page":"G1102","DOI":"10.1152\/ajpgi.00095.2016","article-title":"Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance","volume":"310","author":"Ilan","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0155","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2174\/138955706778742722","article-title":"Glycolipids as immune modulatory tools","volume":"6","author":"Lalazar","year":"2006","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0160","doi-asserted-by":"crossref","first-page":"G917","DOI":"10.1152\/ajpgi.00105.2005","article-title":"Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes","volume":"289","author":"Margalit","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/jpet.106.104950","article-title":"Glucocerebroside ameliorates the metabolic syndrome in OB\/OB mice","volume":"319","author":"Margalit","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0170","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.molimm.2009.07.030","article-title":"Decreased STAT-1 phosphorylation by a thio analogue of beta-d-glucosylceramide is associated with altered NKT lymphocyte polarization","volume":"47","author":"Ben Ya'acov","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0175","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1016\/j.molimm.2008.05.009","article-title":"Modulation of intracellular machinery by beta-glycolipids is associated with alteration of NKT lipid rafts and amelioration of concanavalin-induced hepatitis","volume":"45","author":"Lalazar","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0180","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.2353\/ajpath.2009.080841","article-title":"Beta-glycoglycosphingolipid-induced alterations of the STAT signaling pathways are dependent on CD1d and the lipid raft protein flotillin-2","volume":"174","author":"Lalazar","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0185","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2249.2009.03971.x","article-title":"Beta-glucosylceramide ameliorates liver inflammation in murine autoimmune cholangitis","volume":"157","author":"Zhang","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/15476910802129620","article-title":"Beta-glycosphingolipids as immune modulators","volume":"5","author":"Adar","year":"2008","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0195","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.3748\/wjg.v13.i44.5799","article-title":"Potential role of NKT regulatory cell ligands for the treatment of immune mediated colitis","volume":"13","author":"El Haj","year":"2007","journal-title":"World J. Gastroenterol."},{"issue":"120","key":"10.1016\/j.bcmd.2016.10.028_bb0200","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00702-012-0842-7","article-title":"Autoimmunity, dendritic cells and relevance for Parkinson's disease","volume":"1996","author":"Koutsilieri","year":"2013","journal-title":"J. Neural Transm. Vienna Austria"},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2016.10.028_bb0205","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1016\/S1353-8020(11)70065-7","article-title":"Neuroinflammation in Parkinson's disease","volume":"18","author":"Hirsch","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0210","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12026-008-8018-0","article-title":"Microglial cells and Parkinson's disease","volume":"41","author":"Qian","year":"2008","journal-title":"Immunol. Res."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0215","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-398314-5.00004-0","article-title":"Inflammation in Parkinson's disease","volume":"88","author":"Tufekci","year":"2012","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0220","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1096\/fj.02-0314fje","article-title":"Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease","volume":"17","author":"Wilms","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0225","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1750-1172-8-140","article-title":"Unfolded protein response in Gaucher disease: from human to Drosophila","volume":"8","author":"Maor","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0230","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddw129","article-title":"The contribution of mutant GBA to the development of Parkinson disease in Drosophila","author":"Maor","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0235","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0240","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0245","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ymgme.2012.04.018","article-title":"Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant \u03b2-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant","volume":"106","author":"Babajani","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0250","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.braindev.2012.05.008","article-title":"The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice","volume":"35","author":"Luan","year":"2013","journal-title":"Brain Dev."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069147","article-title":"Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in Drosophila eye","volume":"8","author":"Suzuki","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2016.10.028_bb0260","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0265","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"Zimran","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0270","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1447-0756.2000.tb01327.x","article-title":"Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome","volume":"26","author":"Laoag-Fernandez","year":"2000","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.bcmd.2016.10.028_bb0275","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12028-011-9642-4","article-title":"High-dose ambroxol reduces pulmonary complications in patients with acute cervical spinal cord injury after surgery","volume":"16","author":"Li","year":"2012","journal-title":"Neurocrit. Care."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616302297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616302297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:34:09Z","timestamp":1761050049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616302297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":55,"alternative-id":["S1079979616302297"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.028","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}